Education
About Us
Working with TipRanks
Follow Us
Delcath Systems (DCTH)
NASDAQ:DCTH
DCTH Stock Chart & Stats
$9.50
-$0.29(-2.36%)
At close: 4:00 PM EST
$9.50
-$0.29(-2.36%)
Day’s Range― - ―
52-Week Range$8.12 - $18.23
Previous CloseN/A
Volume96.76K
Average Volume (3M)466.62K
Market Cap
$356.67M
Enterprise Value$275.62M
Total Cash (Recent Filing)$88.91M
Total Debt (Recent Filing)$965.00K
Price to Earnings (P/E)1157.0
Beta1.74
Next Earnings
Mar 31, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.02
Shares Outstanding35,313,717
10 Day Avg. Volume558,149
30 Day Avg. Volume466,624
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)4.99
Price to Sales (P/S)9.23
P/FCF Ratio-17.84
Enterprise Value/Market Cap0.77
Enterprise Value/Revenue3.46
Enterprise Value/Gross Profit4.01
Enterprise Value/Ebitda19.31
Forecast
1Y Price Target
$24.50Price Target Upside157.89% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Data And Guideline InclusionPublication of CHOPIN clinical data could increase physician adoption of Hepzato and support inclusion in clinical guideline compendia, boosting treatment referrals.
Commercial Adoption And Sales InfrastructureReaching targeted active treatment sites along with significant growth in procedure volume and expected sales force expansion may accelerate patient referrals and revenue growth.
Pipeline Expansion And New IndicationsInitiation of trials in breast and colorectal cancer, including expansion into liver metastases, may expand Hepzato's addressable patient population if clinical results are favorable.
Bears Say
Clinical Adoption Barriers From GuidelinesClinical guidelines that favor enrollment in trials over Hepzato treatment may constrain therapy uptake and limit commercial growth.
Execution, Regulatory And Competition RiskA slowdown in activating new treatment centers, combined with regulatory and competitive risks, creates uncertainty around achieving site expansion and broader commercial execution.
Profitability Pressure From SpendingExpansion of research programs and buildup of the regional sales force will raise research and selling expenses and may pressure profitability.
Delcath Systems News
DCTH FAQ
What was Delcath Systems’s price range in the past 12 months?
Delcath Systems lowest stock price was $8.12 and its highest was $18.23 in the past 12 months.
What is Delcath Systems’s market cap?
Delcath Systems’s market cap is $356.67M.
When is Delcath Systems’s upcoming earnings report date?
Delcath Systems’s upcoming earnings report date is Mar 31, 2026 which is in 46 days.
How were Delcath Systems’s earnings last quarter?
Delcath Systems released its earnings results on Nov 04, 2025. The company reported $0.02 earnings per share for the quarter, beating the consensus estimate of -$0.004 by $0.024.
Is Delcath Systems overvalued?
According to Wall Street analysts Delcath Systems’s price is currently Undervalued.
Does Delcath Systems pay dividends?
Delcath Systems does not currently pay dividends.
What is Delcath Systems’s EPS estimate?
Delcath Systems’s EPS estimate is -0.07.
How many shares outstanding does Delcath Systems have?
Delcath Systems has 35,313,717 shares outstanding.
What happened to Delcath Systems’s price movement after its last earnings report?
Delcath Systems reported an EPS of $0.02 in its last earnings report, beating expectations of -$0.004. Following the earnings report the stock price went down -4.622%.
Which hedge fund is a major shareholder of Delcath Systems?
Currently, no hedge funds are holding shares in DCTH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Delcath Systems Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$24.50 (157.89% Upside)
$24.50 (157.89% Upside)
Blogger Sentiment
Bullish
DCTH Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 778.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $137.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.7%
Last 30 Days ▼ 7.9%
Last 30 Days ▼ 7.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-38.76%
12-Months-Change
Fundamentals
Return on Equity
1.94%
Trailing 12-Months
Asset Growth
292.33%
Trailing 12-Months
Company Description
Delcath Systems
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
DCTH Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed picture with significant advancements in clinical trials and revenue growth, but also highlighted challenges such as reduced revenue per kit and increased operating expenses impacting profitability.View all DCTH earnings summariesDCTH Stock 12 Month Forecast
Average Price Target
$24.50
▲(157.89% Upside)
Technical Analysis
Ownership Overview
30.89% Insiders
6.91% Mutual Funds
25.50% Other Institutional Investors
28.25% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---